Comparative Pharmacology
Head-to-head clinical analysis: NICORETTE MINT versus NICOTINE POLACRILEX ORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICORETTE MINT versus NICOTINE POLACRILEX ORAL.
NICORETTE (MINT) vs NICOTINE POLACRILEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine binds to nicotinic acetylcholine receptors (nAChRs) in the brain, stimulating dopamine release in the mesolimbic pathway, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Nicotine polacrilex acts as a nicotinic acetylcholine receptor agonist, binding to α4β2 receptors in the ventral tegmental area and mediating dopamine release in the nucleus accumbens, which reduces withdrawal symptoms and cravings by providing a lower and slower peak of nicotine compared to smoking.
For smoking cessation, apply one 2 mg or 4 mg lozenge (mint) every 1-2 hours as needed for cravings, up to 15 lozenges per day. Use 4 mg lozenge if first cigarette is within 30 minutes of waking. Do not chew; allow to dissolve slowly (20-30 minutes). Frequency should be tapered after 6 weeks.
2 mg or 4 mg lozenge or gum as needed up to 20 lozenges or pieces of gum per day; typical dosing: 1 lozenge or piece of gum every 1-2 hours while awake, up to 12 per day. For smoking cessation, initial dose based on smoking habits: if first cigarette within 30 minutes of waking, use 4 mg; if >30 minutes, use 2 mg.
None Documented
None Documented
2 hours (range 1-4) for nicotine; terminal half-life 10-12 hours for cotinine; clinical context: short t½ requires frequent dosing. Half-life prolonged in hepatic impairment.
The terminal elimination half-life of nicotine is approximately 2 hours (range 1-4 hours) after intravenous administration or smoking, but after polacrilex gum use, absorption is slower and half-life may be slightly prolonged due to continued absorption. Clinical context: short half-life necessitates frequent dosing to maintain levels for smoking cessation.
Renal: 60-80% as metabolites (cotinine, nicotine N-oxide), 10-20% unchanged; biliary/fecal: <10%
Nicotine and its metabolites are primarily excreted renally. About 10-20% of nicotine is excreted unchanged in urine, with the remainder as metabolites, mainly cotinine. Urinary pH affects excretion; acidic urine increases clearance. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Smoking cessation aid
Smoking cessation aid